The Impact of Biosimilars in Canada

The Impact of Biosimilars in Canada 2018.png

The Impact of Biosimilars in Canada

CARE ™ Faculty members Dr. John Marshall (McMaster University), Dr. Brian Feagan (Western University) and Karen Voin (Vice President of the Canadian Life and Health Insurance Association) met in July 2018 to discuss biosimilars in Canada. 

This publication on the Impact of Biosimilars in Canada focuses on a physician’s and payer’s perspective and includes discussion on the following:

  • Major biosimilar updates that have happened since CARE™’s last video discussion

  • The evolution in stakeholder attitude towards biosimilars in clinical practice

  • The challenges proposed by biosimilar adoption (pharmacovigilance)

  • The difference in biosimilar opinion from one specialty group to another (e.g. oncology versus hematology)   

  • The challenges of tracking biosimilars and possible ways to overcome those challenges

  • Factors that limit biosimilar adoption in Canada

  • The potential benefits of biosimilar associated cost savings

The CARE™ Faculty has produced a number of outputs on the subject on biosimilars including numerous video clips and publications.

For a recent publication titled “Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching” co-authored by CARE™ Faculty member Dr. Brian Feagan, and published in the Applied Health Economics and Health Policy Journal, click here:

Contributing Faculty


Dr. John Marshall, MD
McMaster University

Dr. Brian Feagan, MD
Western University

Karen Voin
Vice President of the Canadian Life and Health Insurance Association

Gastroenterology Primer on Biosimilars


Supportive CARE™ Primer on Biosimilars

The primer offers information on biologics and biosimilars, with a focus on the basic science, regulatory pathways, clinical data and implications, as well as legal perspectives. 

  • Biologic therapy has revolutionized the treatment of many gastroenterological disorders, and drastically improved patient outcomes.
  • Many biologic therapies used in gastroenterology have gone, or are going off patent, and competitive biosimilars are being introduced. 
  • Biosimilars not only have implications for specialty fields, but also for the general delivery of health care in Canada. 

What follows is a primer on biologics and biosimilars, updated to reflect a gastroenterological perspective. This educational report was created in conjunction with CARE™ Faculty Member Dr. John Marshall (McMaster University), with review and input from Usha Chauhan (NP, McMaster University), to provide a nursing perspective. This report details the basic science, management and regulatory pathways, legal perspectives and recent clinical data on biosimilars. It is informed by various CARE™ faculties and recent biosimilar news.

This Gastroenterology Biosimilars Primer is written as of May 2018 and is subject to update and refinement. It is based upon a multi-disciplinary CARE™ Primer on Biosimilars (produced Fall 2017). For more information on CARE™ visit To access the comprehensive primer visit:

Contributing Authors

John K. Marshall, MD
CARE™ Gastroenterology Faculty
McMaster University


Usha Chauhan, NP
Supportive CARE™ Faculty
McMaster University

Scott Edwards, B.Sc., Pharm
Dr. H. Bliss Murphy Cancer Centre

Rob Laister, PhD
Princess Margaret Cancer Centre

Jason Thomas, RPh, B.Sc., Pharm
Juravinski Cancer Centre